D
NervGen Pharma Corp.
NGENF
$2.06
$0.0030.15%
D
Sell
12/27/2024Upgraded
NervGen Pharma Corp. (NGENF) was upgraded to D- from E+ on 12/27/2024 due to an increase in the volatility index.
NervGen Pharma Corp. (NGENF) was upgraded to D- from E+ on 12/27/2024 due to an increase in the volatility index.
E
Sell
12/9/2024Downgrade
NervGen Pharma Corp. (NGENF) was downgraded to E+ from D- on 12/9/2024 due to a decline in the volatility index and valuation index.
NervGen Pharma Corp. (NGENF) was downgraded to E+ from D- on 12/9/2024 due to a decline in the volatility index and valuation index.
D
Sell
11/22/2024Upgraded
NervGen Pharma Corp. (NGENF) was upgraded to D- from E+ on 11/22/2024 due to an increase in the growth index, volatility index and solvency index. Earnings per share increased from -$0.0818 to -$0.0547.
NervGen Pharma Corp. (NGENF) was upgraded to D- from E+ on 11/22/2024 due to an increase in the growth index, volatility index and solvency index. Earnings per share increased from -$0.0818 to -$0.0547.
E
Sell
11/15/2024Downgrade
NervGen Pharma Corp. (NGENF) was downgraded to E+ from D- on 11/15/2024 due to a major decline in the growth index, volatility index and solvency index. Earnings per share declined from -$0.0289 to -$0.0818, operating cash flow declined 26.85% from -$2.41M to -$3.06M, and the quick ratio declined from 2.35 to 1.73.
NervGen Pharma Corp. (NGENF) was downgraded to E+ from D- on 11/15/2024 due to a major decline in the growth index, volatility index and solvency index. Earnings per share declined from -$0.0289 to -$0.0818, operating cash flow declined 26.85% from -$2.41M to -$3.06M, and the quick ratio declined from 2.35 to 1.73.
D
Sell
7/2/2024Upgraded
NervGen Pharma Corp. (NGENF) was upgraded to D- from E+ on 7/2/2024 due to an increase in the volatility index and total return index.
NervGen Pharma Corp. (NGENF) was upgraded to D- from E+ on 7/2/2024 due to an increase in the volatility index and total return index.
E
Sell
6/17/2024Downgrade
NervGen Pharma Corp. (NGENF) was downgraded to E+ from D- on 6/17/2024 due to a decline in the volatility index and growth index. Operating cash flow declined 6.18% from -$2.27M to -$2.41M, and EBIT declined 2.87% from -$3.58M to -$3.69M.
NervGen Pharma Corp. (NGENF) was downgraded to E+ from D- on 6/17/2024 due to a decline in the volatility index and growth index. Operating cash flow declined 6.18% from -$2.27M to -$2.41M, and EBIT declined 2.87% from -$3.58M to -$3.69M.
D
Sell
12/26/2023Upgraded
NervGen Pharma Corp. (NGENF) was upgraded to D- from E+ on 12/26/2023 due to an increase in the volatility index.
NervGen Pharma Corp. (NGENF) was upgraded to D- from E+ on 12/26/2023 due to an increase in the volatility index.
E
Sell
12/11/2023Downgrade
NervGen Pharma Corp. (NGENF) was downgraded to E+ from D- on 12/11/2023 due to a decline in the solvency index, volatility index and valuation index. Debt to equity increased from 0.01 to 0.02, and the quick ratio declined from 1.66 to 1.33.
NervGen Pharma Corp. (NGENF) was downgraded to E+ from D- on 12/11/2023 due to a decline in the solvency index, volatility index and valuation index. Debt to equity increased from 0.01 to 0.02, and the quick ratio declined from 1.66 to 1.33.
D
Sell
10/18/2023Upgraded
NervGen Pharma Corp. (NGENF) was upgraded to D- from E+ on 10/18/2023 due to an increase in the volatility index, total return index and valuation index.
NervGen Pharma Corp. (NGENF) was upgraded to D- from E+ on 10/18/2023 due to an increase in the volatility index, total return index and valuation index.
E
Sell
9/28/2023Downgrade
NervGen Pharma Corp. (NGENF) was downgraded to E+ from D- on 9/28/2023 due to a decline in the volatility index.
NervGen Pharma Corp. (NGENF) was downgraded to E+ from D- on 9/28/2023 due to a decline in the volatility index.
D
Sell
9/13/2023Upgraded
NervGen Pharma Corp. (NGENF) was upgraded to D- from E+ on 9/13/2023 due to a noticeable increase in the growth index, volatility index and total return index. Operating cash flow increased 57.92% from -$3.54M to -$1.49M.
NervGen Pharma Corp. (NGENF) was upgraded to D- from E+ on 9/13/2023 due to a noticeable increase in the growth index, volatility index and total return index. Operating cash flow increased 57.92% from -$3.54M to -$1.49M.
E
Sell
4/21/2023Downgrade
NervGen Pharma Corp. (NGENF) was downgraded to E+ from D- on 4/21/2023 due to a decline in the volatility index.
NervGen Pharma Corp. (NGENF) was downgraded to E+ from D- on 4/21/2023 due to a decline in the volatility index.
D
Sell
4/5/2023Upgraded
NervGen Pharma Corp. (NGENF) was upgraded to D- from E+ on 4/5/2023 due to an increase in the volatility index and total return index.
NervGen Pharma Corp. (NGENF) was upgraded to D- from E+ on 4/5/2023 due to an increase in the volatility index and total return index.
E
Sell
3/28/2023Downgrade
NervGen Pharma Corp. (NGENF) was downgraded to E+ from D- on 3/28/2023 due to a decline in the volatility index and total return index.
NervGen Pharma Corp. (NGENF) was downgraded to E+ from D- on 3/28/2023 due to a decline in the volatility index and total return index.
D
Sell
3/14/2023Downgrade
NervGen Pharma Corp. (NGENF) was downgraded to D- from D on 3/14/2023 due to a decline in the total return index.
NervGen Pharma Corp. (NGENF) was downgraded to D- from D on 3/14/2023 due to a decline in the total return index.
D
Sell
2/23/2023Upgraded
NervGen Pharma Corp. (NGENF) was upgraded to D from D- on 2/23/2023 due to an increase in the total return index and volatility index.
NervGen Pharma Corp. (NGENF) was upgraded to D from D- on 2/23/2023 due to an increase in the total return index and volatility index.
D
Sell
2/8/2023Downgrade
NervGen Pharma Corp. (NGENF) was downgraded to D- from D on 2/8/2023 due to a major decline in the total return index and volatility index.
NervGen Pharma Corp. (NGENF) was downgraded to D- from D on 2/8/2023 due to a major decline in the total return index and volatility index.
D
Sell
5/31/2022Upgraded
NervGen Pharma Corp. (NGENF) was upgraded to D from D- on 5/31/2022 due to an increase in the total return index.
NervGen Pharma Corp. (NGENF) was upgraded to D from D- on 5/31/2022 due to an increase in the total return index.
D
Sell
5/13/2022Downgrade
NervGen Pharma Corp. (NGENF) was downgraded to D- from D on 5/13/2022 due to a decline in the growth index, solvency index and volatility index. Operating cash flow declined 47.22% from -$2.27M to -$3.34M, the quick ratio declined from 15.76 to 11.52, and EBIT declined 20.05% from -$3.29M to -$3.95M.
NervGen Pharma Corp. (NGENF) was downgraded to D- from D on 5/13/2022 due to a decline in the growth index, solvency index and volatility index. Operating cash flow declined 47.22% from -$2.27M to -$3.34M, the quick ratio declined from 15.76 to 11.52, and EBIT declined 20.05% from -$3.29M to -$3.95M.
D
Sell
5/5/2022Upgraded
NervGen Pharma Corp. (NGENF) was upgraded to D from D- on 5/5/2022 due to an increase in the volatility index.
NervGen Pharma Corp. (NGENF) was upgraded to D from D- on 5/5/2022 due to an increase in the volatility index.
D
Sell
4/20/2022Downgrade
NervGen Pharma Corp. (NGENF) was downgraded to D- from D on 4/20/2022 due to a significant decline in the total return index.
NervGen Pharma Corp. (NGENF) was downgraded to D- from D on 4/20/2022 due to a significant decline in the total return index.
D
Sell
11/22/2021Upgraded
NervGen Pharma Corp. (NGENF) was upgraded to D from D- on 11/22/2021 due to an increase in the total return index, growth index and solvency index. Operating cash flow increased 6.87% from -$1.72M to -$1.6M, and the quick ratio increased from 7.34 to 7.64.
NervGen Pharma Corp. (NGENF) was upgraded to D from D- on 11/22/2021 due to an increase in the total return index, growth index and solvency index. Operating cash flow increased 6.87% from -$1.72M to -$1.6M, and the quick ratio increased from 7.34 to 7.64.
D
Sell
11/8/2021Downgrade
NervGen Pharma Corp. (NGENF) was downgraded to D- from D on 11/8/2021 due to a major decline in the growth index, valuation index and solvency index. Operating cash flow declined 68.95% from -$1.02M to -$1.72M, EBIT declined 27.9% from -$1.76M to -$2.25M, and earnings per share declined from -$0.0501 to -$0.0591.
NervGen Pharma Corp. (NGENF) was downgraded to D- from D on 11/8/2021 due to a major decline in the growth index, valuation index and solvency index. Operating cash flow declined 68.95% from -$1.02M to -$1.72M, EBIT declined 27.9% from -$1.76M to -$2.25M, and earnings per share declined from -$0.0501 to -$0.0591.
D
Sell
11/20/2020Upgraded
NervGen Pharma Corp. (NGENF) was upgraded to D from D- on 11/20/2020 due to a major increase in the growth index, volatility index and solvency index. The quick ratio increased from 6.33 to 23.68, earnings per share increased from -$0.0624 to -$0.0479, and EBIT increased 15.27% from -$1.89M to -$1.6M.
NervGen Pharma Corp. (NGENF) was upgraded to D from D- on 11/20/2020 due to a major increase in the growth index, volatility index and solvency index. The quick ratio increased from 6.33 to 23.68, earnings per share increased from -$0.0624 to -$0.0479, and EBIT increased 15.27% from -$1.89M to -$1.6M.
D
Sell
10/14/2020Downgrade
NervGen Pharma Corp. (NGENF) was downgraded to D- from D on 10/14/2020 due to a noticeable decline in the growth index and volatility index. EBIT declined 36.21% from -$1.39M to -$1.89M, and earnings per share declined from -$0.047 to -$0.0624.
NervGen Pharma Corp. (NGENF) was downgraded to D- from D on 10/14/2020 due to a noticeable decline in the growth index and volatility index. EBIT declined 36.21% from -$1.39M to -$1.89M, and earnings per share declined from -$0.047 to -$0.0624.
D
Sell
6/2/2020Upgraded
NervGen Pharma Corp. (NGENF) was upgraded to D from D- on 6/2/2020 due to a noticeable increase in the growth index. Earnings per share increased from -$0.0762 to -$0.047, EBIT increased 36.85% from -$2.2M to -$1.39M, and operating cash flow increased 6.74% from -$1.52M to -$1.42M.
NervGen Pharma Corp. (NGENF) was upgraded to D from D- on 6/2/2020 due to a noticeable increase in the growth index. Earnings per share increased from -$0.0762 to -$0.047, EBIT increased 36.85% from -$2.2M to -$1.39M, and operating cash flow increased 6.74% from -$1.52M to -$1.42M.
D
Sell
5/19/2020Downgrade
NervGen Pharma Corp. (NGENF) was downgraded to D- from D on 5/19/2020 due to a decline in the total return index, volatility index and valuation index.
NervGen Pharma Corp. (NGENF) was downgraded to D- from D on 5/19/2020 due to a decline in the total return index, volatility index and valuation index.
D
Sell
5/1/2020Upgraded
NervGen Pharma Corp. (NGENF) was upgraded to D from D- on 5/1/2020 due to an increase in the total return index, growth index and valuation index. Operating cash flow increased 6.16% from -$1.62M to -$1.52M.
NervGen Pharma Corp. (NGENF) was upgraded to D from D- on 5/1/2020 due to an increase in the total return index, growth index and valuation index. Operating cash flow increased 6.16% from -$1.62M to -$1.52M.
D
Sell
1/2/2020Upgraded
NervGen Pharma Corp. (NGENF) was upgraded to D- from E on 1/2/2020 due to a noticeable increase in the volatility index and total return index.
NervGen Pharma Corp. (NGENF) was upgraded to D- from E on 1/2/2020 due to a noticeable increase in the volatility index and total return index.
E
Sell
10/1/2019Upgraded
NervGen Pharma Corp. (NGENF) was upgraded to E from E- on 10/1/2019 due to a noticeable increase in the growth index and total return index. Earnings per share increased from -$0.1177 to -$0.0412, EBIT increased 48.41% from -$2.27M to -$1.17M, and operating cash flow increased 47.97% from -$1.95M to -$1.01M.
NervGen Pharma Corp. (NGENF) was upgraded to E from E- on 10/1/2019 due to a noticeable increase in the growth index and total return index. Earnings per share increased from -$0.1177 to -$0.0412, EBIT increased 48.41% from -$2.27M to -$1.17M, and operating cash flow increased 47.97% from -$1.95M to -$1.01M.
E
Sell
6/27/2019None
NervGen Pharma Corp. (NGENF) was downgraded to E- from U on 06/27/2019.
NervGen Pharma Corp. (NGENF) was downgraded to E- from U on 06/27/2019.
OTC PK
04/08/2025 10:57AM Eastern
Quotes delayed
